| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥64.0B | ¥62.9B | +1.7% |
| Operating Income | ¥4.6B | ¥6.3B | -27.1% |
| Ordinary Income | ¥4.8B | ¥6.9B | -29.8% |
| Net Income | ¥7.8B | ¥11.7B | -33.3% |
| ROE | 9.2% | 14.7% | - |
FY2025 consolidated results: Revenue ¥64.0B (YoY +1.7%), Operating Income ¥4.6B (-27.1%), Ordinary Income ¥4.8B (-29.8%), Net Income ¥7.8B (-33.3%). Revenue achieved modest growth of +1.7% while operating profit declined sharply by 27.1%, indicating deteriorating operational profitability. The company maintained a high gross profit margin of 54.4%, but SG&A expenses of ¥30.2B (47.2% of revenue) compressed operating margins to 7.2% from prior year's 10.0%. Net income benefited significantly from extraordinary gains including ¥3.5B gain on sale of securities, which masked underlying operational challenges. This represents a "revenue up, profit down" pattern with operating leverage turning negative.
Revenue grew modestly by +1.7% to ¥64.0B, driven by geographic diversification. Japan sales increased to ¥40.8B (+1.2%), China/Hong Kong declined slightly to ¥18.7B (-3.2%), while Taiwan expanded to ¥3.4B (+29.6%) and other regions grew to ¥1.1B (+69.4%). The revenue stability reflects resilient demand in core markets despite market headwinds. Gross profit reached ¥34.8B with a strong margin of 54.4%, indicating robust pricing power and cost management at the production level. However, SG&A expenses remained elevated at ¥30.2B, absorbing 47.2% of revenue and compressing operating margin to 7.2% from 10.0% YoY, a deterioration of 2.8pt. Operating income declined 27.1% to ¥4.6B due to this margin compression.
Non-operating income contributed positively with ¥0.4B in gains including ¥0.2B interest income and ¥0.4B FX gains, partially offsetting ¥0.1B in interest expenses. This resulted in ordinary income of ¥4.8B (-29.8% YoY). The most significant factor in net income performance was extraordinary items: ¥5.0B in extraordinary income primarily from ¥3.5B gain on sale of securities, offset by ¥0.3B in extraordinary losses including ¥0.2B impairment loss. These non-recurring factors elevated profit before tax to ¥9.6B and enabled net income of ¥7.8B despite operational profit decline. Income tax expense was remarkably low at ¥0.3B, resulting in an effective tax rate of approximately 3.1%, significantly below statutory rates due to extraordinary gain treatment.
This represents a "revenue up, profit down" pattern at the operating level, with net income supported by non-recurring gains masking fundamental operational challenges.
The Pharmaceuticals segment represents the core business with revenue of ¥57.7B (90.3% share) and operating income of ¥15.7B, delivering a healthy margin of 27.3%. This segment decreased slightly in revenue by 0.1% YoY from ¥57.8B but experienced significant profit compression with operating income declining 19.2% from ¥19.5B to ¥15.7B, indicating margin pressure of approximately 6.0pt deterioration. The segment remains highly profitable and generates substantially all consolidated operating profit.
The Infection Control segment recorded revenue of ¥6.2B (9.7% share) with an operating loss of ¥2.5B, resulting in a negative margin of 41.0%. This segment saw revenue growth of +21.9% from ¥5.1B, indicating market expansion, but operating losses deepened from ¥4.7B loss to ¥2.5B loss, representing a ¥2.2B improvement in absolute loss despite remaining deeply unprofitable. The segment continues to drag on consolidated profitability.
Corporate/unallocated costs amounted to approximately ¥8.4B, consistent with prior year levels, representing overhead and shared service expenses. The stark profitability contrast between segments (Pharmaceuticals +27.3% margin vs. Infection Control -41.0% margin) highlights strategic challenges in achieving profitability across the portfolio. The Pharmaceuticals segment's margin compression from approximately 33.7% to 27.3% is the primary driver of consolidated operating profit decline.
[Profitability] ROE 9.2% represents solid capital efficiency though trending below the reported dupont-analyzed ROE of 10.8%. Operating margin declined to 7.2% from 10.0% YoY, a compression of 2.8pt, reflecting significant operational leverage deterioration. Net profit margin of 12.2% appears healthy but is artificially elevated by ¥3.5B extraordinary gain on securities sale; excluding this non-recurring item, normalized net margin would approximate 6.8%, indicating structural profitability challenges. Gross profit margin remained robust at 54.4%, demonstrating strong product positioning. [Cash Quality] Cash and deposits totaled ¥42.6B, providing 17.0x coverage of short-term debt and representing 34.7% of total assets, indicating exceptional liquidity reserves. Operating cash flow of ¥8.1B represents 1.04x of net income, confirming reasonable cash conversion though slightly below unity when adjusted for extraordinary gains. [Investment Efficiency] Total asset turnover of 0.52x reflects capital-intensive operations with significant working capital embedded. Operating working capital of ¥59.2B represents 92.6% of revenue, with concerning efficiency metrics: DSO of 140 days indicating extended receivables collection, DIO of 203 days reflecting high inventory levels particularly in work-in-process (¥8.0B representing 49.5% of total inventory), and combined CCC of 309 days signaling substantial room for improvement. [Financial Health] Equity ratio of 69.4% demonstrates conservative capitalization well above safety thresholds. Current ratio of 336.1% and quick ratio of 323.8% indicate strong liquidity buffers. Interest-bearing debt of ¥7.9B results in debt-to-equity ratio of 9.3% and debt-to-EBITDA of 1.09x, confirming minimal leverage and strong debt servicing capacity with interest coverage well above safety levels.
Operating cash flow of ¥8.1B represents 1.04x of net income, indicating reasonable earnings quality though this ratio is somewhat distorted by the ¥3.5B extraordinary gain on securities sale; normalizing for this non-recurring item would suggest operating CF of approximately 1.48x normalized operating earnings, confirming solid cash generation from core operations. The operating CF increased substantially by 124.9% YoY from ¥3.6B, driven by improved profit before tax of ¥9.6B and favorable working capital movements including ¥0.6B reduction in inventories and ¥0.8B increase in payables, partially offset by ¥0.2B increase in receivables. Income taxes paid were minimal at ¥0.3B, consistent with the low effective tax rate. Investing cash flow of ¥1.4B comprised CapEx of ¥2.9B offset by proceeds from asset disposals including securities sales, resulting in a CapEx-to-depreciation ratio of 1.10x indicating continued growth investment above maintenance levels. Free cash flow reached ¥9.6B (operating CF ¥8.1B plus investing CF ¥1.4B), representing robust cash generation capacity. Financing cash flow of ¥-12.3B reflected significant cash deployment, likely for debt repayment and shareholder returns, demonstrating disciplined capital allocation. The company's cash position of ¥42.6B provides substantial financial flexibility, though the elevated working capital of ¥59.2B with CCC of 309 days suggests opportunities for cash flow enhancement through operational efficiency improvements in receivables collection and inventory management.
Ordinary income of ¥4.8B versus operating income of ¥4.6B shows minimal net non-operating contribution of approximately ¥0.2B, representing 0.3% of revenue. Non-operating income totaled ¥0.4B comprising primarily ¥0.2B in interest income and ¥0.4B in FX gains, demonstrating conservative treasury management and modest currency exposure benefits. Non-operating expenses of ¥0.1B were minimal, consisting mainly of ¥0.1B interest expense on the modest debt load. The critical quality concern emerges from extraordinary items: ¥5.0B in extraordinary income dominated by ¥3.5B gain on sale of investment securities, representing 54.7% of revenue and 7.8x operating income, indicating net income is heavily dependent on non-recurring asset monetization rather than operational performance. This one-time gain explains the disconnect between operating income decline of 27.1% and net income decline of only 33.3%. Excluding extraordinary items, normalized pre-tax income would approximate ¥4.9B, highlighting that sustainable earnings power is substantially below reported net income of ¥7.8B. Operating cash flow of ¥8.1B slightly exceeds net income, ordinarily a positive quality indicator, but this relationship is distorted by the non-cash extraordinary gain. The comprehensive income of ¥5.4B reflects ¥1.5B negative FX translation adjustment and ¥2.3B negative valuation difference on securities, indicating unrealized losses that partially offset the realized gains. Overall earnings quality is compromised by heavy reliance on non-recurring gains masking operational profit deterioration, warranting investor caution regarding sustainability of reported profitability.
Full-year guidance projects revenue of ¥72.0B (+12.5% YoY) and operating income of ¥5.0B (+8.9% YoY), with ordinary income of ¥5.2B (+7.7% YoY). Current progress rates show revenue at 88.9% (¥64.0B actual vs ¥72.0B target) and operating income at 91.8% (¥4.6B vs ¥5.0B), both running ahead of the typical full-year pro-rata expectation of 100% completion, suggesting conservative guidance or anticipated H2 weakness. The implied H2 performance would require revenue of approximately ¥8.0B and operating income of ¥0.4B to achieve full-year targets, representing significant deceleration from H1 run rates. Operating margin guidance of 6.9% for full year (¥5.0B/¥72.0B) implies further margin compression from current 7.2%, indicating management expects continued operational headwinds. The revenue growth expectation of +12.5% versus current +1.7% actual suggests anticipated strong H2 acceleration, likely dependent on Infection Control segment recovery and Pharmaceuticals segment stabilization. EPS forecast of ¥10.95 implies full-year net income of approximately ¥5.5B based on outstanding shares of 50.2M, substantially below current ¥7.8B due to absence of recurring extraordinary gains. The guidance assumes normalized operations without repeat of securities sale gains, providing more realistic earnings expectations. Key risks to guidance achievement include sustained SG&A pressure, Infection Control segment profitability recovery pace, and working capital efficiency improvements required to sustain operating cash flow. The conservative nature of guidance relative to current progress provides modest downside protection but highlights management's cautious outlook for operational recovery.
The company declared zero dividends for the current period with no interim or year-end dividend distributions. The XBRL data indicates a payout ratio of 18.0%, which appears inconsistent with zero actual dividend payments and may reflect a policy target rather than actual distribution. Based on reported net income of ¥7.8B and 50.2M shares outstanding, the 18% payout ratio would imply potential annual dividend of approximately ¥2.8 per share, but no such distribution was implemented. The absence of dividends despite strong cash position of ¥42.6B and positive free cash flow of ¥9.6B suggests management is prioritizing capital retention for operational improvements, working capital optimization, or strategic investments. No share buyback activity was disclosed in the reporting period. The zero dividend policy represents a departure from potential shareholder return capacity, as free cash flow would comfortably support modest distributions while maintaining financial flexibility. The decision to retain all earnings appears driven by management's focus on addressing operational challenges including Infection Control segment losses, working capital inefficiencies, and potential growth investments. For investors seeking income, the current policy provides no yield despite adequate financial capacity for distributions. The total return ratio effectively stands at 0% absent any dividends or buybacks, indicating an accumulation phase focused on business repositioning rather than immediate shareholder cash returns.
Infection Control segment profitability recovery represents the primary operational risk, with the segment posting ¥2.5B operating loss (41.0% negative margin) despite 21.9% revenue growth. Continued losses of this magnitude would offset Pharmaceuticals segment profit contribution and prevent consolidated margin recovery. The segment's path to breakeven remains uncertain and prolonged losses could necessitate strategic review or restructuring, potentially resulting in additional impairment charges beyond the ¥0.2B recognized in the current period.
Working capital efficiency deterioration poses significant cash flow and return on capital risks, with CCC extending to 309 days driven by DSO of 140 days and DIO of 203 days. The elevated work-in-process inventory of ¥8.0B (49.5% of total inventory) suggests manufacturing process bottlenecks or demand forecasting challenges. If working capital continues to absorb cash, operating cash flow sustainability would be threatened despite adequate current liquidity, potentially constraining growth investments or requiring external financing.
Earnings quality dependency on non-recurring gains creates sustainability and predictability risks, as ¥3.5B securities sale gain represented 44.9% of reported net income. The exhaustion of investment securities portfolio (reduced from ¥4.6B prior year to minimal current holdings) eliminates this profit source going forward. Without operational margin recovery, normalized earnings power approximates ¥4.3B to ¥4.9B range (versus ¥7.8B reported), representing 38-44% lower sustainable profitability and requiring significant operational improvements to maintain investor confidence in earnings trajectory.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the pharmaceutical manufacturing and infection control products industry. Based on proprietary analysis, the company's ROE of 9.2% positions competitively within the pharmaceutical sector which typically exhibits ROE ranges of 8-12% for mid-sized players, though trailing industry leaders who achieve 15%+ returns. The equity ratio of 69.4% substantially exceeds typical industry median of 45-55%, indicating more conservative capitalization that provides financial stability but potentially underutilizes leverage for returns enhancement. Operating margin of 7.2% falls below pharmaceutical industry median of approximately 12-15%, reflecting the drag from unprofitable Infection Control segment and elevated SG&A burden; the core Pharmaceuticals segment margin of 27.3% aligns more closely with profitable pharmaceutical manufacturers. The company's working capital intensity with CCC of 309 days significantly exceeds industry best practices of 90-150 days, indicating material efficiency gap versus peers. Cash holdings of 34.7% of assets exceed industry norms of 15-25%, providing exceptional liquidity buffers but suggesting potential for more productive capital deployment. The absence of dividend payments contrasts with pharmaceutical industry norms where established players typically maintain 30-50% payout ratios, positioning the company as growth/turnaround oriented rather than income-focused. Overall industry positioning reflects strong financial stability and core pharmaceutical segment competitiveness, but operational efficiency and profitability metrics trail sector benchmarks requiring operational improvements to achieve industry-standard returns.
The company demonstrates significant divergence between financial stability and operational performance, with exceptional balance sheet strength (69.4% equity ratio, ¥42.6B cash, 336% current ratio) contrasting sharply with deteriorating operating profitability (operating income -27.1%, margin compression to 7.2%). This disconnect creates a turnaround situation where substantial financial resources provide runway for operational restructuring, but execution risks remain elevated until Infection Control segment achieves breakeven and Pharmaceuticals segment stabilizes margins.
Working capital management emerges as the critical efficiency frontier, with CCC of 309 days and work-in-process inventory representing 49.5% of total inventory signaling substantial cash trapped in operations. A normalized CCC of 180-200 days would release approximately ¥20-25B in cash, representing 20-25% of current assets and providing significant resources for growth investment or shareholder returns without operational improvement. Management's ability to drive working capital optimization will be a key value creation lever and indicator of operational competence.
Earnings sustainability concerns warrant cautious interpretation of reported profitability, as ¥3.5B extraordinary gain on securities sale represents non-recurring income equivalent to 76% of operating income. The depletion of investment securities portfolio eliminates this future profit source, requiring operational margin recovery of approximately 300-400 basis points to maintain absolute profit levels. The company's normalized earnings power of ¥4-5B range (versus ¥7.8B reported) should inform valuation assessments, with current results overstating sustainable profitability by approximately 56-95%. Investors should focus on operating income trajectory and segment-level margin trends rather than net income as the primary performance metric until operational fundamentals stabilize.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.